Physician profile
Sarah E Long
NPI 1376825380
$8,424.52
in general payments reported to CMS, 2019-2025
28 companies · $1,955 in 2025
The $1,955 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,103 · 2022: $2,152 · 2023: $1,654 · 2024: $1,561 · 2025: $1,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,169.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,073.01 | 2021-2025 | |
| Janssen Biotech, INC. | $874.42 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $816.55 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $717.94 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $472.81 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $440.64 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $374.46 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $331.85 | 2022-2024 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $267.10 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $253.11 | 2021-2025 | Ocaliva |
| Pfizer INC. | $232.89 | 2022-2025 | |
| Genzyme Corporation | $220.62 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $183.43 | 2021-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $182.68 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $150.33 | 2022-2025 | Sucraid, Sucraid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $111.95 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $110.71 | 2022 | |
| Amgen INC. | $108.64 | 2021-2023 | Avsola, Amjevita |
| Organon LLC | $81.46 | 2023-2025 | Hadlima, Renflexis |
| Braintree Laboratories, INC. | $79.04 | 2021-2025 | Suflave |
| Lilly USA, LLC | $75.12 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $65.76 | 2024 | Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $54.15 | 2023-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $50.45 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $38.05 | 2024-2025 | Rebyota |
| Nestle Healthcare Nutrition INC. | $26.61 | 2023 | |
| Mauna Kea Technologies, INC. | $16.94 | 2024 | |
| Redhill Biopharma INC. | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.